Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Bought by Kraematon Investment Advisors Inc.

Kraematon Investment Advisors Inc. raised its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE) by 24.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 19,885 shares of the company’s stock after buying an additional 3,885 shares during the period. Kraematon Investment Advisors Inc.’s holdings in Wave Life Sciences were worth $246,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of WVE. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Wave Life Sciences by 23.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock worth $37,000 after acquiring an additional 856 shares during the period. Profund Advisors LLC purchased a new stake in Wave Life Sciences during the 2nd quarter worth about $53,000. Point72 DIFC Ltd acquired a new stake in Wave Life Sciences in the 3rd quarter valued at about $98,000. Orion Portfolio Solutions LLC purchased a new position in shares of Wave Life Sciences in the 3rd quarter valued at about $123,000. Finally, XTX Topco Ltd acquired a new position in shares of Wave Life Sciences during the third quarter worth about $126,000. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Insiders Place Their Bets

In other Wave Life Sciences news, CEO Paul Bolno sold 50,000 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $15.00, for a total transaction of $750,000.00. Following the transaction, the chief executive officer now directly owns 217,351 shares of the company’s stock, valued at approximately $3,260,265. This trade represents a 18.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Chris Francis sold 36,000 shares of Wave Life Sciences stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $576,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 137,234 shares of company stock valued at $2,059,671 over the last quarter. Company insiders own 29.10% of the company’s stock.

Wave Life Sciences Trading Down 1.4 %

WVE opened at $11.31 on Friday. Wave Life Sciences Ltd. has a one year low of $3.50 and a one year high of $16.74. The business’s 50-day simple moving average is $13.80 and its 200-day simple moving average is $9.88.

Analyst Upgrades and Downgrades

Several research firms have commented on WVE. Raymond James upgraded shares of Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $13.00 to $22.00 in a report on Wednesday, October 16th. StockNews.com downgraded shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, November 13th. Truist Financial raised their price target on Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. Mizuho upped their price objective on Wave Life Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Finally, Leerink Partners increased their price objective on Wave Life Sciences from $20.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Wave Life Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $22.22.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.